Anaxis Pharma is an Australian Biotech company developing novel inhibitors / modulators of cell death, specifically necroptosis, an inflammatory form of programmed cell death. This process, involving both kinases and pseudokinases, is central to and dysregulated in chronic inflammatory disease. Targeting necroptosis fulfils an unmet medical need for patients with diseases including irritable bowel disease, Crohn’s disease, liver fibrosis and reperfusion injury.